Our findings hold significant translational implications: A predictive model integrating EIF2B4 expression levels with TMB and PD-L1 status may optimize treatment stratification for hepatocellular carcinoma patients receiving immune checkpoint therapy. This evidence concerns the gene EIF2B4 and hepatocellular carcinoma.